```
=> d his

     (FILE 'HOME' ENTERED AT 08:24:10 ON 14 OCT 2004)

     FILE 'CASREACT' ENTERED AT 08:26:21 ON 14 OCT 2004
L1             STRUCTURE UPLOADED
L2           0 S L1
L3           1 S L1 FUL
L4             STRUCTURE UPLOADED
L5           0 S L4
L6           1 S L4 FUL

     FILE 'CAPLUS' ENTERED AT 08:35:44 ON 14 OCT 2004
L7      389101 S COUPLING
L8        1570 S ARYL BROMIDE#
L9        4345 S ARYL HALIDE#
L10       5458 S L8 OR L9
L11     198737 S KETONE#
L12     389101 S L7
L13        140 S L7 AND L10 AND L11
L14     143277 S PALLADIUM
L15         82 S L14 AND L13
L16       5173 S BRONSTED
L17     614351 S BRONSTED OR BASE
L18         15 S L17 AND L15

=> d bib abs kwic 1-15

L18  ANSWER 1 OF 15  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2004:218750  CAPLUS
DN   140:253348
TI   Preparation of biaryls from aryl halides and
     arylboranes
IN   Nishida, Mayumi; Tagata, Takeshi
PA   Koei Chemical Co., Ltd., Japan
SO   Jpn. Kokai Tokkyo Koho, 16 pp.
     CODEN: JKXXAF
DT   Patent
LA   Japanese
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   JP 2004083530        A2    20040318    JP 2002-249649         20020828
PRAI JP 2002-249649             20020828
OS   MARPAT 140:253348
AB   Biaryls are prepared by reaction of aryl halides with
     arylboronic acids or dialkylarylboranes in solvents in the presence of (a)
     Pd catalysts, which are insol. in solvents and show specific x-ray
     photoelectron spectra, (b) bases, and (c) phosphines.  P-ClC6H4CN was
     treated with PhB(OH)2 in 1,2-dimethoxyethane in the presence of PPh3,
     KHCO3, and Pd/C at 80° for 8 h to give 67% 4-cyanobiphenyl.
TI   Preparation of biaryls from aryl halides and
     arylboranes
AB   Biaryls are prepared by reaction of aryl halides with
     arylboronic acids or dialkylarylboranes in solvents in the presence of (a)
     Pd catalysts, which are insol. in solvents and show specific x-ray
     photoelectron spectra, (b) bases, and (c) phosphines.  P-ClC6H4CN was
     treated with PhB(OH)2 in 1,2-dimethoxyethane in the presence of PPh3,
     KHCO3, and Pd/C at 80° for 8 h to give 67% 4-cyanobiphenyl.
ST   biaryl prepn aryl halide coupling
     arylborane; palladium catalyst aryl halide
     coupling arylborane; phosphine base palladium
```

=> d his

(FILE 'HOME' ENTERED AT 08:24:10 ON 14 OCT 2004)

FILE 'CASREACT' ENTERED AT 08:26:21 ON 14 OCT 2004
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 1 S L1 FUL

=> d bib abs crd l3

L3 ANSWER 1 OF 1 CASREACT COPYRIGHT 2004 ACS on STN
AN 108:94141 CASREACT
TI 2-Ethynylbenzenealkanamines. A new class of calcium entry blockers
AU Carson, J. R.; Almond, H. R.; Brannan, M. D.; Carmosin, R. J.; Flaim, S. F.; Gill, A.; Gleason, M. M.; Keely, S. L.; Ludovici, D. W.; et al.
CS McNeil Pharm., Spring House, PA, 19477-0776, USA
SO Journal of Medicinal Chemistry (1988), 31(3), 630-6
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
GI



I

AB A series of 2-[aryl(alkyl)ethynyl]benzenealkanamines was synthesized. The compds. exhibit antihypertensive activity in spontaneously hypertensive rats and coronary vasodilator activity with minimal neg. inotropic activity in the Langendorff guinea pig heart in vitro. They exert their activity by inhibition of Ca2+ influx across cell membranes. Optimal activity is found among the N-(arylethyl)-5-methoxy-α-methyl-2-(phenylethynyl)benzeneethanamines and -propanamines, e.g., I.

RX(25) OF 149



59%

=>

=> d his

(FILE 'HOME' ENTERED AT 08:24:10 ON 14 OCT 2004)

FILE 'CASREACT' ENTERED AT 08:26:21 ON 14 OCT 2004
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 1 S L1 FUL
L4 STRUCTURE UPLOADED
L5 0 S L4
L6 1 S L4 FUL

=> d crd bib

L6 ANSWER 1 OF 1 CASREACT COPYRIGHT 2004 ACS on STN

RX(3) OF 149



82%

RX(25) OF 149



59%

AN 108:94141 CASREACT
TI 2-Ethynylbenzenealkanamines. A new class of calcium entry blockers
AU Carson, J. R.; Almond, H. R.; Brannan, M. D.; Carmosin, R. J.; Flaim, S. F.; Gill, A.; Gleason, M. M.; Keely, S. L.; Ludovici, D. W.; et al.
CS McNeil Pharm., Spring House, PA, 19477-0776, USA
SO Journal of Medicinal Chemistry (1988), 31(3), 630-6
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English

=>

:\Program Files\Stnexp\Queries\rxn3.str



hain nodes :
1 2 3 11 18 19 20 24
ing nodes :
5 6 7 8 9 10 12 13 14 15 16 17
ing/chain nodes :
4 21
hain bonds :
1-2 2-3 2-4 8-11 15-18 18-19 19-20 19-21
ing bonds :
5-6 5-10 6-7 7-8 8-9 9-10 12-13 12-17 13-14 14-15 15-16 16-17
xact/norm bonds :
2-3 19-20
xact bonds :
1-2 2-4 8-11 15-18 18-19 19-21
ormalized bonds :
5-6 5-10 6-7 7-8 8-9 9-10 12-13 12-17 13-14 14-15 15-16 16-17

atch level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:CLASS 24:CLASS
ragments assigned reagent role:
containing 24
ragments assigned product role:
containing 12
ragments assigned reactant/reagent role:
containing 1
containing 5